ArticleNature communications2022
Biosynthesis of mushroom-derived type II ganoderic acids by engineered yeast.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Multiomics Analysis across the Life Cycle Identifies ZnJournal of agricultural and food chemistry · 2026Article
- Genomic features and the transcriptional regulation of secondary metabolite biosynthesis of endophytic fungusMicrobial genomics · 2026Article
- Development of a CRISPR/Cas9 Genome Editing System in DikaryoticJournal of fungi (Basel, Switzerland) · 2026Article
- Insights into intraspecific variation and genotyping ofIMA fungus · 2026Article
- Enhanced ganoderic acids production by using thermotolerant Ganoderma tsugae at high-temperature liquid cultivation.PloS one · 2026Article
- Screening of Monokaryotic Strains ofJournal of fungi (Basel, Switzerland) · 2025Article
- Single-cell sequencing and mass spectrometry imaging reveal the multicellular compartmentalization map of plant triterpenes: A ginsenoside in Panax ginseng example.Plant biotechnology journal · 2025Article
- Blue Light Receptor WC-2 Regulates Ganoderic Acid Biosynthesis inJournal of fungi (Basel, Switzerland) · 2025Article
- Article
- Decoding and reprogramming of the biosynthetic networks of mushroom-derived bioactive type II ganoderic acids in yeast.Cell discovery · 2025Article
- Unraveling bioactive potential and production inChinese herbal medicines · 2025Review
- Genome-wide identification of CYP450 in Ganoderma lucidum and expression analysis of genes related to ganoderic acid synthesis.Archives of microbiology · 2025Article
- Metabolic Response ofMicroorganisms · 2025Article
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Paclobutrazol induces triterpenoid biosynthesis via downregulation of the negative transcriptional regulator SlMYB in Sanghuangporus lonicericola.Communications biology · 2025Article
- Integrated Transcriptomic and Targeted Metabolomic Analysis Reveals the Key Genes Involved in Triterpenoid Biosynthesis ofJournal of fungi (Basel, Switzerland) · 2025Article
- Overexpression of tRNA mFrontiers in microbiology · 2025Article
- Recent trends in the elucidation of complex triterpene biosynthetic pathways in horticultural trees.Horticulture research · 2025Article
- Towards engineering agaricomycete fungi for terpenoid production.Journal of industrial microbiology & biotechnology · 2024Review
- Whole-Genome Sequence Analysis ofJournal of fungi (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type II ganoderic acids (GAs) produced by the traditional medicinal mushroom Ganoderma are a group of triterpenoids with superior biological activities. However, challenges in the genetic manipulation of the native producer, low level of accumulation in the farmed mushroom, the vulnerabilities of the farming-based supply chain, and the elusive biosynthetic pathway have hindered the efficient production of type II GAs. Here, we assemble the genome of type II GAs accumulating G. lucidum accession, screen cytochrome P450 enzymes (CYPs) identified from G. lucidum in baker's yeast, identify key missing CYPs involved in type II GAs biosynthesis, and investigate the catalytic reaction sequence of a promiscuous CYP. Then, we engineer baker's yeast for bioproduciton of GA-Y (3) and GA-Jb (4) and achieve their production at higher level than those from the farmed mushroom. Our findings facilitate the further deconvolution of the complex GA biosynthetic network and the development of microbial cell factories for producing GAs at commercial scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.